Skip to main content

Table 1 Patient characteristics

From: Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study

 

Training cohort

Internal validation cohort

External validation cohort

P value

Sample size, patients

420

205

136

 

PRNN events within 1-year (%)

120 (28.6)

60 (29.3)

36 (26.5)

0.847

PRNN events in total (%)

148 (35.2)

66 (32.2)

45 (33.1)

0.728

Median age at recurrence, years (IQR)

47.0 (40.8–53.0)

48.0 (42.0–55.0)

49.0 (41.0–54.0)

0.228

Sex (%)

   

0.759

 Male

316 (75.2)

152 (74.1)

98 (72.1)

 

 Female

104 (24.8)

53 (25.9)

38 (27.9)

 

Median BMI, kg/m2 (IQR)

22.3 (20.4–24.2)

22.2 (19.8–24.2)

22.1 (20.0–24.5)

0.814

History of diabetes (%)

14 (3.3)

4 (2.0)

9 (6.6)

0.070

History of hypertension (%)

31 (7.4)

14 (6.8)

5 (3.7)

0.312

Recurrent T category (%)a

   

 < 0.001

 rT1

21 (5.0)

7 (3.4)

18 (13.2)

 

 rT2

46 (11.0)

24 (11.7)

32 (23.5)

 

 rT3

208 (49.5)

108 (52.7)

58 (42.6)

 

 rT4

145 (34.5)

66 (32.2)

28 (20.6)

 

Synchronous nodal recurrence (%)

128 (30.5)

61 (29.8)

46 (33.8)

0.703

Recurrent histology (%)

   

 < 0.001

 WHO III

397 (94.5)

192 (93.7)

108 (79.4)

 

 WHO II

4 (1.0)

4 (2.0)

3 (2.2)

 

 WHO I

19 (4.5)

9 (4.4)

25 (18.4)

 

Median disease-free interval, months (IQR)

34.0 (20.0–57.0)

34.0 (22.0–65.0)

36.5 (20.0–59.0)

0.606

Median GTVrecurrence, cm3 (IQR)

40.6 (23.7–70.0)

35.7 (20.0–62.0)

26.0 (18.0–51.0)

 < 0.001

Re-radiotherapy type (%)

   

0.004

 IMRT

375 (89.3)

187 (91.2)

134 (98.5)

 

 Helical tomotherapy

45 (10.7)

18 (8.8)

2 (1.5)

 

Median re-irradiation dose, Gy (IQR)b

61.1 (60.0–64.0)

61.1 (59.7–64.0)

64.0 (61.1–64.0)

 < 0.001

Re-irradiation dose (%)b

   

 < 0.001

  < 64 Gy

281 (66.9)

137 (66.8)

40 (29.4)

 

  ≥ 64 Gy, < 68 Gy

119 (28.3)

56 (27.3)

87 (64.0)

 

  ≥ 68 Gy

20 (4.8)

12 (5.9)

9 (6.6)

 

Median accumulated GTV dose, Gy (IQR)b

131.1 (129.7–134.0)

131.1 (129.7–134.0)

134.0 (130.0–134.0)

0.013

Accumulated GTV dose (%)b

   

 < 0.001

  < 134 Gy

295 (70.2)

143 (69.8)

61 (44.9)

 

  ≥ 134 Gy, < 140 Gy

106 (25.2)

53 (25.9)

71 (52.2)

 

  ≥ 140 Gy

19 (4.5)

9 (4.4)

4 (2.9)

 

Combination with chemotherapy (%)

291 (69.3)

137 (66.8)

91 (66.9)

0.775

Median hemoglobin level, g/L (IQR)

137.0 (126.0–148.0)

136.0 (127.0–148.0)

136.5 (128.0–145.3)

0.959

  1. IQR interquartile range, BMI body mass index, GTV gross tumor volume, IMRT intensity modulated radiotherapy
  2. aPatients were restaged according to the 8th American Joint Committee on Cancer Union for International Cancer Control (UICC/AJCC) staging system
  3. bDoses were converted to equivalent dose in 2-Gy fraction (EQD2) values using the following equation: total dose * (dose per fraction + 10) / (2 + 10), where 10 = a/b ratio for head and neck cancer
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us